{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T11:09:10Z","timestamp":1775560150801,"version":"3.50.1"},"reference-count":61,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Bladder cancer is one of the most common malignancies of the urinary tract and poses a significant clinical challenge due to its biological heterogeneity and high rates of recurrence and progression. Urothelial carcinoma represents the predominant histological subtype, ranging from non-muscle-invasive disease with relatively favorable outcomes to aggressive muscle-invasive and metastatic forms associated with poor prognosis. Accurate diagnosis, staging, prognostic stratification, and assessment of treatment response are therefore essential for optimal patient management. The objective of this review is to summarize and critically evaluate the current evidence on the role of positron emission tomography\/computed tomography (PET\/CT) in bladder cancer, with particular emphasis on [18F]FDG PET\/CT and non-FDG radiotracers. Materials and Methods: A narrative review of the available literature was performed, focusing on clinical studies, review articles, and guideline documents addressing the use of PET\/CT in bladder cancer. The literature search included articles published between 2000 and 2025, while earlier landmark studies were selectively included if considered historically important for understanding the development of PET\/CT imaging in bladder cancer. The initial search yielded over 500 records; after screening titles and abstracts, more than 100 articles were selected for full-text evaluation. The analyzed evidence encompasses the clinical applications of [18F]FDG PET\/CT and alternative radiotracers, including choline-, acetate-, methionine-, and sodium fluoride-based tracers, and fibroblast activation protein inhibitors (FAPI), across different stages of disease and clinical settings. Results: Conventional imaging modalities, such as computed tomography and magnetic resonance imaging, provide important anatomical information but remain limited in the evaluation of lymph node involvement, early metastatic disease, treatment response, and disease recurrence. Despite limitations related to physiological urinary excretion, [18F]FDG PET\/CT has demonstrated clinical value in selected scenarios, particularly for staging, prognostic assessment, detection of recurrence, and response evaluation. To overcome FDG-related constraints, several non-FDG radiotracers have been investigated. Among these, FAPI PET\/CT has emerged as a promising modality due to its ability to target the tumor stroma, potentially improving lesion detectability and tumor-to-background contrast. Conclusions: This review summarizes and critically evaluates current evidence on the role of PET\/CT in bladder cancer, with a focus on [18F]FDG PET\/CT and non-FDG radiotracers. The discussed studies highlight their applications in primary diagnosis, staging, prognostic assessment, detection of recurrence, and evaluation of treatment response, as well as their respective advantages and limitations. Furthermore, potential future directions for PET\/CT imaging in clinical practice are outlined, emphasizing the need for further research to clarify the optimal use of established and emerging radiotracers.<\/jats:p>","DOI":"10.3390\/medicina62040703","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T09:40:31Z","timestamp":1775554831000},"page":"703","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Positron Emission Tomography\/Computed Tomography in Bladder Cancer: The Role of [18F]FDG and Non-FDG Radiotracers"],"prefix":"10.3390","volume":"62","author":[{"given":"Hanna","family":"Fali\u0144ska","sequence":"first","affiliation":[{"name":"Military Institute of Medicine\u2014National Research Institute, Department of Nuclear Medicine, Szaser\u00f3w 128, 04-141 Warsaw, Poland"},{"name":"Affidea Poland, Plac Europejski 2, 00-844 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewa","family":"Witkowska-Patena","sequence":"additional","affiliation":[{"name":"Military Institute of Medicine\u2014National Research Institute, Department of Nuclear Medicine, Szaser\u00f3w 128, 04-141 Warsaw, Poland"},{"name":"Affidea Poland, Plac Europejski 2, 00-844 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karolina","family":"Krzy\u017canowska","sequence":"additional","affiliation":[{"name":"Affidea Poland, Plac Europejski 2, 00-844 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miros\u0142aw","family":"Dziuk","sequence":"additional","affiliation":[{"name":"Military Institute of Medicine\u2014National Research Institute, Department of Nuclear Medicine, Szaser\u00f3w 128, 04-141 Warsaw, Poland"},{"name":"Affidea Poland, Plac Europejski 2, 00-844 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Strauss, V.I.W., Mariani, G., Volterrani, D., and Larson, S.M. (2017). Diagnostic applications of nuclear medicine: Kidney and bladder cancer. Nuclear Oncology: From Pathophysiology to Clinical Applications, Springer. [2nd ed.].","DOI":"10.1007\/978-3-319-26067-9"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1097\/MNM.0b013e3283567473","article-title":"Catheter-assisted 18F-FDG-PET\/CT imaging or primary bladder cancer: A prospective study","volume":"33","author":"Mertens","year":"2012","journal-title":"Nucl. Med. Commun."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"145","DOI":"10.4103\/0972-3919.112718","article-title":"Detecting primary bladder cancer using delayed 18F-2-fluoro-2-deoxy-D-glucose-positron emission tomography\/computed tomography imaging after forced diuresis","volume":"27","author":"Mertens","year":"2012","journal-title":"Indian J. Nucl. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1097\/RLU.0000000000000398","article-title":"Proposal of a new acquisition protocol for bladder cancer visualization with 18F-FDG PET\/CT","volume":"40","author":"Chondrogiannis","year":"2015","journal-title":"Clin. Nucl. Med."},{"key":"ref_5","first-page":"214","article-title":"Dual phase 18F-tluorodeoxyglucose positron emission tomography\/computed tomography with forced diuresis in diagnostic imaging evaluation of bladder cancer","volume":"32","author":"Ozdemir","year":"2013","journal-title":"Rev. Esp. Med. Nucl. Imagen Mol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1097\/RLU.0000000000001780","article-title":"Enhanced application of 18F-FDG PET\/CT in bladder cancer by adding early dynamic acquisition to a standard delayed PET protocol","volume":"42","author":"Yoon","year":"2017","journal-title":"Clin. Nucl. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1159\/000351964","article-title":"Is fluorine-18 fluorodeoxyglucose positron emission tomography useful for detecting bladder lesions? A meta-analysis of the literature","volume":"92","author":"Wang","year":"2014","journal-title":"Urol. Int."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/RLU.0000000000000772","article-title":"Comparison of coregistration accuracy of pelvic structures between sequential and simultaneous imaging during hybrid PET\/MRI in patients with bladder cancer","volume":"40","author":"Rosenkrantt","year":"2015","journal-title":"Clin. Nucl. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1097\/RLU.0000000000001432","article-title":"Prospective pilot study to evaluate the incremental value of PET information in patients with bladder cancer undergoing 18F-FDG simultaneous PET\/MRI","volume":"42","author":"Rosenkrantz","year":"2017","journal-title":"Clin. Nucl. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.1200\/JCO.2008.20.6722","article-title":"Prospective study of [18F]fluorodeoxyglucose positron emission tomography\/computed tomography for staging of muscle-invasive bladder carcinoma","volume":"27","author":"Kibel","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.urology.2013.10.032","article-title":"18F-fluorodeoxyglucoze positron emission tomography\/computed tomography aids staging and predicts mortality in patients with muscle invasive bladder cancer","volume":"83","author":"Mertens","year":"2014","journal-title":"Urology"},{"key":"ref_12","unstructured":"(2026, January 15). Muscle-Invasive and Metastatic Bladder Cancer. Available online: http:\/\/uroweb.org\/guideline\/bladder-cancer-muscle-invasive-and-metastatic\/."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s00259-012-2294-6","article-title":"Diuretic 18F-FDG PET\/CT imaging for detection and locoregional staging of urinary bladder cancer: Prcspcctive evaluation ofa novel technique","volume":"40","author":"Nayak","year":"2013","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/bju.12608","article-title":"Role of fluorodeoxyglucose positron emission tomography (FDG PET)-computed tomography (CT) in the staging of bladder cancer","volume":"114","author":"Goodfellow","year":"2014","journal-title":"BJU Int."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1111\/j.1464-410X.2010.09212.x","article-title":"Evaluation of fluorodeoxyglucose positron-emission tomography with computed tomography for staging of urothelial carcinoma","volume":"106","author":"Lodde","year":"2010","journal-title":"BJU Int."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/iju.12045","article-title":"18F-fluorodeoksyglucoze positron emission tomography-computed tomography for preoperative lymph node staging in patients undergoing radical cystectomy for bladder cancer. a prospective study","volume":"20","author":"Ansquer","year":"2013","journal-title":"Int. J. Ural."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.eururo.2009.05.014","article-title":"FDG-PET\/CT for the preoperative lymph node staging of invasive bladder cancer","volume":"57","author":"Swinnen","year":"2010","journal-title":"Eur. Urol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1007\/s00259-005-1886-9","article-title":"FDG-PET for preoperative staging of bladder cancer","volume":"32","author":"Drieskens","year":"2005","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s001200050244","article-title":"Das Lymphknotenstaging des Harnblasenkarzinoms mit der Positronenemissionstomographie [Lymph node staging of bladder neck carcinoma with positron emission tomography]","volume":"38","author":"Bachor","year":"1999","journal-title":"Urol. A"},{"key":"ref_20","first-page":"615","article-title":"Preliminary assessment of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with bladder cancer","volume":"24","author":"Kosuda","year":"1997","journal-title":"Eur. J. Nucl. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1464-410X.2009.09118.x","article-title":"Lymph node mapping in patients with bladder cancer undergoing radical cystectomy and lymph node dissection to the level of the inferior mesenteric artery","volume":"106","author":"Jensen","year":"2010","journal-title":"BJU Int."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/bju.12109","article-title":"Impact of 18F-fluorodeoxyglucose (FDG)-positron-emission tomography\/computed tomography (PET\/CT) on management of patients with carcinoma invading bladder muscle","volume":"112","author":"Mertens","year":"2013","journal-title":"BJU Int."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.1200\/JCO.2010.28.7052","article-title":"Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography\/computed tomography in bladder cancer","volume":"28","author":"Apolo","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000092937","article-title":"Evaluation of duorodeoxyglucose positron emission tomography imaging in metastatic transitional cell carcinoma with and without prior chemotherapy","volume":"77","author":"Liu","year":"2006","journal-title":"Urol. Int."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3109\/00365599.2010.544672","article-title":"Preoperative lymph-node staging of invasive urothelial bladder cancer with 18F-nuorodeoxyg1ucose positron emission tomography\/computed axial tomography and magnetic resonance imaging: Correlation with histopathology","volume":"45","author":"Jensen","year":"2011","journal-title":"Scand. J. Urol. Nephrol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s00345-016-1772-z","article-title":"The diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography and computed tomography in staging bladder cancer: A single-institution study and a systematic review with meta-analysis","volume":"34","author":"Soubra","year":"2016","journal-title":"World J. Urol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"764","DOI":"10.2967\/jnumed.106.036350","article-title":"18F-FDG PET\/CT delayed images after diuretic for restaging invasive bladder cancer","volume":"48","author":"Anjos","year":"2007","journal-title":"J. Nucl. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4103\/0971-3026.59746","article-title":"Forced diuresis and dual-phase F-fluorodeoxyglucose. PET\/CT scan for restaging of urinary bladder cancers","volume":"20","author":"Harkirat","year":"2010","journal-title":"Indian J. Radiol. Imaging"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s10147-007-0720-8","article-title":"[F-18]-Fluorodeoxyglucose PET and PET-CT in diagnostic imaging evaluation of locally recurrent and metastatic bladder transitional cell carcinoma","volume":"13","author":"Jadvar","year":"2008","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.ejrad.2011.07.018","article-title":"Clinical value of FIDG PET or PET\/CT in urinary bladder cancer: A systemic leview and meta-analysis","volume":"81","author":"Lu","year":"2012","journal-title":"Eur. J. Radiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.euf.2017.06.005","article-title":"Detection of lymph node metastasis in patients with bladder cancer using maximum standardised uptake value and 18F-fluorodeoxyglucose positron emission tomography\/computed tomography: Results from a highvolume centre including long-term follow-up","volume":"5","author":"Bouchelouche","year":"2019","journal-title":"Eur. Urol. Focus"},{"key":"ref_32","first-page":"235.e15","article-title":"[18F]Fluoro-Deoxy-Glucose positron emission tomography to evaluate lymph node involvement in patients with muscle-invasive bladder cancer receiving neoadjuvant pembrolizumab","volume":"39","author":"Marandino","year":"2021","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.cpet.2015.03.002","article-title":"PET\/computed tomography in renal, bladder, and testicular cancer","volume":"10","author":"Bouchelouche","year":"2015","journal-title":"PET Clin."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s12149-012-0614-3","article-title":"Is whole-body fluorine-18 fluorodeoxyglucose PET\/CT plus additional pelvic images (oral hydration-voiding-refilling) useful for detecting recurrent bladder cancer?","volume":"26","author":"Yang","year":"2012","journal-title":"Ann. Nucl. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s00259-016-3500-8","article-title":"Recurrent bladder carcinoma: Clinical and prognostic role of 18F-FDG PET\/CT","volume":"44","author":"Alongi","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.eururo.2012.05.048","article-title":"A Systematic Review of Neoadjuvant and Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer","volume":"62","author":"Meeks","year":"2012","journal-title":"Eur. Urol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.juro.2012.11.009","article-title":"FDG-positron emission tomography\/computerized tomography for monitoring the response of pelvic lymph node metastasis to neoadjuvant chemotherapy for bladder cancer","volume":"189","author":"Mertens","year":"2013","journal-title":"J. Urol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1080\/21681805.2017.1321579","article-title":"[18F]Fluorodeoxyglucose-positron emission tomography\/computed tomography response evaluation can predict histological response at surgery after induction chemotherapy for oligometastatic bladder cancer","volume":"51","author":"Kollberg","year":"2017","journal-title":"Scand. J. Urol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1007\/s11255-017-1637-4","article-title":"FDG-PET\/CT for response evaluation of invasive bladder cancer following neoadjuvant chemotherapy","volume":"49","author":"Vegt","year":"2017","journal-title":"Int. Urol. Nephrol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.clgc.2014.03.007","article-title":"Interim fluorine-18 fluorodeoxyglucose positron emission tomography for early metabolic assessment of therapeutic response to chemotherapy for metastatic transitional cell carcinoma","volume":"12","author":"Giannatempo","year":"2014","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_41","first-page":"938","article-title":"Value of 11C-Choline PET and Contrast-Enhanced CT for Staging of Bladder Cancer: Correlation with Histopathologic Findings","volume":"47","author":"Picchio","year":"2006","journal-title":"J. Nucl. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.juro.2006.04.018","article-title":"Contribution of 11C-Choline Positron Emission Tomography\/Computerized Tomography to Preoperative Staging of Advanced Transitional Cell Carcinoma","volume":"176","author":"Gofrit","year":"2006","journal-title":"J. Ural."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e308","DOI":"10.1097\/RLU.0000000000000342","article-title":"Diagnostic Accuracy of 11C-Choline PET\/CT in Preoperative Lymph Node Staging of Bladder Cancer: A Systematic Comparison with Contrast-Enhanced CT and Histologic Findings","volume":"39","author":"Brunocilla","year":"2014","journal-title":"Clin. Nucl. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1007\/s00259-002-0881-7","article-title":"Visualisation of bladder cancer using 11C-choline PET: First clinical experience","volume":"29","author":"Pruim","year":"2002","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1159\/000357686","article-title":"Prognostic value of llC-choline PET\/CT and CT for predicting survival of bladder cancer patients treated with radical cystectomy","volume":"93","author":"Maurer","year":"2014","journal-title":"Urol. Int."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/RLU.0000000000000573","article-title":"11C-choline PET\/CT for restagingof bladder cancer","volume":"40","author":"Graziani","year":"2015","journal-title":"Clin. Nucl. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.eururo.2011.12.009","article-title":"Diagnostic efficacy of [11C]choline positron emission tomography\/computed tomography compared with conventional computed tomography in lymph node staging of patients with bladder cancer prior to radical cystectomy","volume":"61","author":"Maurer","year":"2012","journal-title":"Eur. Urol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"4131","DOI":"10.1016\/j.ejrad.2012.06.010","article-title":"Prospective evaluation of MRI, 11C-acetate PET\/CT and contrast enhanced CT for staging of bladder cancer","volume":"81","author":"Vargas","year":"2012","journal-title":"Eur. J. Radiol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1097\/RLU.0b013e31824786e7","article-title":"11C-Acetate PET\/CT in Bladder Urothelial Carcinoma: Intraindividual Comparison with 11C-Choline","volume":"37","author":"Orevi","year":"2012","journal-title":"Clin. Nucl. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1177\/02841851960371P137","article-title":"Positron emission tomography in the diagnosis and staging of urinary bladder cancer","volume":"37","author":"Ahlstrom","year":"1996","journal-title":"Acta Radiol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/j.1464-410X.1994.tb07123.x","article-title":"Positron emission tomography with L-methyl-11C-methionine in the monitoring of therapy response in muscle-invasive transitional cell carcinoma of the urinary bladder","volume":"74","author":"Letocha","year":"1994","journal-title":"Br. J. Urol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/RLU.0b013e31828da5cc","article-title":"Comparison of 18F fluoride PET\/CT and 99mTc-MDP bone scan in the detection of skeletal metastases in urinary bladder carcinoma","volume":"38","author":"Chakraborty","year":"2013","journal-title":"Clin. Nucl. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.2967\/jnumed.118.210443","article-title":"Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein","volume":"59","author":"Lindner","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2967\/jnumed.119.227967","article-title":"68Ga-FAPI PET\/CT: Tracer Uptake in 28 Different Kinds of Cancer","volume":"60","author":"Kratochwil","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2967\/jnumed.120.245084","article-title":"FAPI-74 PET\/CT Using Either 18F-AlF or Cold-Kit 68Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients","volume":"62","author":"Giesel","year":"2021","journal-title":"J. Nucl. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s11307-022-01715-3","article-title":"Head-to-head Intra-individual Comparison of [68Ga]-FAPI and [18F]-FDG PET\/CT in Patients with Bladder Cancer","volume":"24","author":"Novruzov","year":"2022","journal-title":"Mol. Imaging Biol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1007\/s00259-022-05761-5","article-title":"Feasibility of [68Ga]Ga-FAPI-46 PET\/CT for detection of nodal and hematogenous spread in high-grade urothelial carcinoma","volume":"49","author":"Unterrainer","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1007\/s00259-024-06595-z","article-title":"[68Ga]Ga-FAPI-46 PET\/CT for locoregional lymph node staging in urothelial carcinoma of the bladder prior to cystectomy: Initial experiences from a pilot analysis","volume":"51","author":"Unterrainer","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1007\/s00259-025-07239-6","article-title":"68Ga-FAPI and 18F-FAPI PET\/CT for detection of nodal metastases prior radical cystectomy in high-risk urothelial carcinoma patients","volume":"52","author":"Unterrainer","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Pabst, K.M., Siegmund, S.C., Holzgreve, A., Schmid, H.P., Bartel, T., Herrmann, K., K\u00fcper, A.T., Aydogdu, C., Kersting, D., and Kesch, C. (2025). Potential value of [68Ga]Ga-FAPI-46 PET in patients with metastatic urothelial carcinoma: A bi-centric analysis. Eur. J. Nucl. Med. Mol. Imaging, Epub ahead of print.","DOI":"10.1007\/s00259-025-07674-5"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"888","DOI":"10.2967\/jnumed.123.267260","article-title":"EAU Section of Urological Imaging. A Systematic Review on the Diagnostic Value of Fibroblast Activation Protein Inhibitor PET\/CT in Genitourinary Cancers","volume":"65","author":"Hagens","year":"2024","journal-title":"J. Nucl. Med."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/4\/703\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T10:26:25Z","timestamp":1775557585000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/4\/703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":61,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["medicina62040703"],"URL":"https:\/\/doi.org\/10.3390\/medicina62040703","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,7]]}}}